Background: We tested whether diazepam, a GABA-ergic drug that also inhibits brain nitric monoxide formation, improves acute stroke prognosis. Methods: 880 patients, randomized within 12 h of acute stroke, received diazepam 10 mg or placebo by rectiole, as soon as possible, followed by 10-mg tablets twice daily for 3 days. Primary outcome was independence (Rankin score <3) at 3 months; secondary outcome was complete recovery (Barthel index ≧95 or Rankin score ≤1). Results: Intention-to-treat analyses on all 849 patients with full follow-up (50.4% on diazepam): odds ratio (OR) 1.14, 95% CI 0.87–1.49 for primary endpoint, and an OR of 1.26 (0.90–1.76) for complete recovery, both favoring diazepam. Adjusted analyses for all stroke patients (843): OR 1.20 (0.87–1.65), and 1.25 (0.89–1.74), respectively, and for all infarct patients (748): OR 1.31 (0.93–1.85), and 1.46 (1.02–2.09; p = 0.037), respectively. Analyses restricted to cardioembolic infarct patients (200) showed treatment benefit for the primary outcome: OR 2.26, 95% CI 1.07–4.76, p = 0.032, and complete recovery: OR 2.65, 95% CI 1.06–6.59, p = 0.037. About one third of ischemic stroke patients had ‘any adverse event’, without any difference between treatment groups. In 95 intracerebral hemorrhage patients, frequency of pneumonia and death were higher in the diazepam group than in the placebo group: 35 and 10%, 22 and 12%, respectively. Conclusions: Although point estimates favored diazepam treatment in various analyses, our data did not confirm our primary hypothesis. Diazepam treatment seems beneficial in cardioembolic infarct patients, is safe in acute ischemic stroke, but may better be avoided in intracerebral hemorrhage.

Keywords:
Diazepam, Neuroprotection, Stroke outcome, Cardioembolic infarction
1.
Tecoma ES, Choi DW: GABA-ergic neocortical neurons are resistant to NMDA receptor-mediated injury. Neurology 1989;39:676–682.
2.
Hossmann KA: Periinfarct depolarisations. Cerebrovasc Brain Metab Rev 1996;8:195–208.
3.
Kelly PT, McCulloch J: The effects of the GABAergic agonist muscimol upon the relationship between local cerebral blood flow and glucose utilization. Brain Res 1983;258:338–342.
4.
Edvinsson L, Krause DN: Pharmacological characterization of GABA receptors mediating vasodilatation of cerebral arteries in situ. Brain Res 1979;173:89–97.
5.
Akaike N, Inomata N, Tokutomi N: Contribution of chloride shifts to the fade of γ-aminobutyric acid-gated currents in frog dorsal root ganglion cells. J Physiol (Lond) 1987;391:219–234.
6.
Twyman RE, MacDonald RL: Antieplileptic drug regulation of GABAA receptor channels; in Tunnicliff G, Raess BU (eds): GABA Mechanisms in Epilepsy. New York, Wiley-Liss, 1991, pp 84–104.
7.
Lodder J, Luijckx GJ, van Raak L, Kessels F: Diazepam treatment to increase the cerebral GABAergic activity in acute stroke: a feasibility study in 104 patients. Cerebrovasc Dis 2000;10:437–440.
8.
Aerden LAM, Steinbusch H, Markerink-van Ittersum M, Lodder J, de Vente J: Dual effect of diazepam on cGMP levels in rat brain slices. Neurochem Res 2004;29:1725–1729.
9.
Aerden LAM, Kessels FAG, Rutten BPF, Lodder J, Steinbusch HWM: Diazepam reduces brain lesion size in a photothrombotic model of focal ischemia in rats. Neurosci Lett 2004;367:76–78.
10.
Fern R, Ransom BR, Stys PK, Waxman SG: Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J Pharmacol Exp Ther 1993;266:1549–1555.
11.
Lodder J, Heuts-van Raak L, Kessels F: GABAergic stimulation by benzodiazepines at stroke onset may ameliorate functional outcome in cardioembolic stroke patients. Cerebrovasc Dis 1996;6:118.
12.
Lyden P: GABA and neuroprotection; in Green AR, Cross AJ (eds): Neuroprotective Agents and Cerebral Ischemia. New York, Academic Press, 1997, pp 233–258.
13.
Schwartz-Bloom RD, Sah R: γ-Aminobutyric acidA neurotransmission and cerebral ischemia. J Neurochem 2001;77:353–371.
14.
Hornig CR, Bauer T, Simon C, Trittmacher S, Dorndorf W: Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke 1993;24:465–468.
15.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
16.
Aerden L, Luijckx GJ, Ricci S, Hilton A, Kessels F, Lodder J: Validation of the Oxfordshire Community Stroke Project (OCSP) syndrome diagnosis derived from a standard symptom list in acute stroke. J Neurol Sci 2004;220:55–58.
17.
De Jong G, van Raak L, Kessels F, Lodder J: Stroke subtype and mortality, a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262–268.
18.
Wahlgren N-G, Bornhov S, Sharma A, Cederin B, Rosolacci T, Ashwood T, Claesson L, for the CLASS Study Group: The Clomethiazole Acute Stroke Study (CLASS): efficacy results in a subgroup of 545 patients with total anterior circulation syndrome. J Stroke Cerebrovasc Dis 1999;8:231–239.
19.
Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E, on behalf of the CLASS-I/H/T Investigators: Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I): final results. Stroke 2002;33:122–129.
20.
Van Raak L, Hilton A, Kessels F, Lodder J: Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke. Control Clin Trials 2002;23:74–79.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.